Comparative Pharmacology
Head-to-head clinical analysis: ACTIVASE versus KINLYTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIVASE versus KINLYTIC.
ACTIVASE vs KINLYTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tissue plasminogen activator that converts plasminogen to plasmin, degrading fibrin clots.
Anticholinergic; muscarinic receptor antagonist; reduces gastrointestinal motility and secretion.
Acute ischemic stroke: 0.9 mg/kg IV (max 90 mg) infused over 60 minutes, with 10% of total dose given as IV bolus over 1 minute. Acute myocardial infarction: Total dose of 100 mg administered IV as a 15 mg bolus, then 50 mg infused over 30 minutes, then 35 mg infused over 60 minutes. Pulmonary embolism: 100 mg IV infused over 2 hours.
100 mg orally twice daily, with or without food.
None Documented
None Documented
4-6 minutes initially (alpha phase), then terminal half-life of 20-40 minutes for fibrin-bound alteplase; clinical context: requires continuous infusion.
Terminal elimination half-life: 12–18 hours; steady-state achieved within 3 days; allows once-daily dosing.
Primarily hepatic clearance; renal excretion negligible, <1% unchanged in urine. Fecal elimination unknown as endogenous enzyme.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; 94% recovered in feces over 10 days, mostly as metabolites.
Category C
Category C
Thrombolytic Agent
Thrombolytic Agent